Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

Magdalena Keller(TU Dortmund University), Rosemarie Marchan(TU Dortmund University)
Journal of Experimental & Clinical Cancer Research
January 20, 2023
Cited by 34


Related Papers